Updates are available Correction dated 2020-07-02
Click to view Correction: https://doi.org/10.1038/s41569-020-0414-8
-
Authors
Jaiswal, Siddhartha
Libby, Peter http://orcid.org/0000-0002-1502-502X
- License Information
-
More Information
Article History
Accepted: 25 July 2019
First Online: 12 August 2019
Change Date: 2 July 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41569-020-0414-8
Competing interests
: S.J. has filed patents related to the topic of this Review and is a consultant for GRAIL. P.L. is an unpaid consultant to, or is involved in clinical trials for, Amgen, AstraZeneca, Esperion Therapeutics, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Novartis, Pfizer, Sanofi-Regeneron and XBiotech. P.L. is a member of the scientific advisory board for Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, IFM Therapeutics, Kowa Pharmaceuticals, Medimmune, Novartis, Olatec Therapeutics and XBiotech. P.L. has a financial interest in XBiotech, a company developing therapeutic human antibodies. P.L.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies.
